INTRODUCTION
Bladder cancer is a lethal disease. A global overview of 2012 showed an incidence of 430,000 cases and a death toll of more than 160,000 cases. [1] The highest mortality rates were seen in Europe, around eight deaths per 100,000 patients. [1] Despite these numbers, the oncological efficacy of any available treatment for bladder cancer has not significantly improved the surivival rates over the past 30 years. [2] RC is a surgical procedure with high postoperative complication rates and there is need for minimizing surgical morbidity. In addition, RC should aim to provide good functional outcomes. The challenge for bladder cancer surgeons is to extirpate the disease and deliver an acceptable postoperative quality of life. In this effort, minimally invasive surgery, and especially robot-assisted RC (RARC) has emerged as an alternative to open surgery.
RARC has been adopted globally, and its use has increased more than 25-fold, from 0.7% to 18 .5% in 2012. [3] Recent data from high-volume centers and registries are reporting promising results. In this review, we discuss the current knowledge on RARC, namely its oncological efficacy, functional outcomes, and safety. Moreover, we will discuss the available evidence comparing RARC versus open RC (ORC).
COMPLICATIONS
Even the most experienced high-volume institutions exhibit high rates of overall complications of RC reaching up to 64%, [4] while the rates of Clavien >3 complications can be as high as 41%. [5] These figures reflect the necessity of centralization of RC in dedicated centers. Another critical factor is to optimize the surgical and clinical pathway of a patient undergoing RC. The use of enhanced recovery protocols (ERP) with RARC utilizing totally intracorporeal techniques for urinary diversion aim to improve patient recovery compared to traditional perioperative management. [6] ERPs have been shown to reduce the length of stay by 1-2 days, while minimizing postoperative ileus, complications, and risk for readmission at 30 days. [7] The ERP concept was introduced by the open colorectal surgeons [8] more than 30 years ago. An effort has been made for ERP to be adopted globally, especially by robotic surgeons, but it remains underutilized, [6] this despite the fact that minimally invasive surgery is included as one of the 22 elements of an ERP for RC. [9] have shown that shifting to the intracorporeal technique is safe and advantageous. [10] In a multi-center, retrospective study of 167 patients undergoing RARC with intracorporeal diversion (ileal conduit: 106; neobladder: 61), and 768 patients undergoing RARC with extracorporeal diversion (ileal conduit: 570; neobladder: 198), the intracorporeal patients had a lower risk of postoperative complication at 90 days postoperatively. (32%) (odds ratio: 0.68; 95% confidence interval, 0.50-0.94; P = 0.02). [10] In addition, gastrointestinal and infectious complications were significantly lower in pateints in whom an intracorporeal approach was used. [10] The obvious advantages of the totally intracorporeal technique are the protection of bowel inside the abdomen, no hypothermia or loss of fluids through osmosis, less bleeding, no need for extensive ureteral dissection, which may lead to ureteral strictures, and minimal surgical trauma. [11] The lack of ERP and underutilization of the intracorporeal approach might jeopardize an accurate interpretation of the results of RC studies. Several studies including published randomized control trials (RCTs), are limited by these factors. In these studies, significant heterogeneity also exists in the types of urinary diversion used. Table 1 shows a chronological evolution of the results of RARC, by looking at two time-periods.(Early period (2008) (2009) (2010) (2011) (2012) and late period (2012-2017)). All the included studies may overlap and may also include periods of surgeons' learning curve. The fact that in the late period, we see more "mature" studies, does not result in significant improvements in the perioperative or oncological outcomes.
Apart from individual RARC series, we have identified 12 systematic analyses [26, 27, 29, [36] [37] [38] [39] [40] [41] [42] and two meta-analyses of the 4 published RCTs [43, 44] since 2013. Table 2 summarises which approach to RC performs significantly better in important surgical and oncological parameters. Apart from operation time, blood loss, positive surgical margins, and survival, other parameters remain debatable with some showing a trend toward RARC's superiority. As an example, as regards overall complications, five studies favor RARC [36, [38] [39] [40] 45] and six studies state that both procedures are equal. [29, 37, 41, 43, 44, 46] As for the length of stay, seven studies are in favor of RARC [36] [37] [38] [39] [40] [41] 45] and three report equal results, [43, 44, 46] and as for lymph node yields, three studies show an advantage of RARC [36, 39, 41] and eight indicate equivalence between the two. [26, 27, 29, 38, [42] [43] [44] [45] It is however clear that RARC performs as expected; as a minimally invasive procedure, providing 
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Dasgupta et al. [12] OS=Overall survival, CSS=Cancer-specific survival, DFS=Disease-free survival, NR=Not reported, RARC=Robot-assisted radical cystectomy, PSM=Positive surgical margins, LNY=Lymph node yield less blood loss and transfusions, less length of stay (LOS) and probably less overall complications, although the latter aspect is not yet verified. In the recently announced results of RAZOR study, which is a 1:1 prospective, randomized, noninferiority trial comparing RARC to ORC, the intraoperative and postoperative transfusion rates as well as mean blood loss were significantly lower for RARC (42% versus 91% and 277.5 cc versus 558.8 cc, respectively).
[47] It is noteworthy that in the same study, no other difference was recorded in postoperative complications. RARC had 58% and ORC had 56% overall complications with similar results in minor and major complications. Clavien 3-5 complications were 18.7% for RARC and 17.6% for ORC. [47] Blood loss and transfusion are considered as minor complications, by the Clavien-Dindo classification system, but it seems that they have a significantly negative impact on the oncological outcome. A possible explanation lies in the induced immunosuppression and the association of blood compatibility with infections.
Six retrospective studies comprising more than 7000 patients reported that transfusion during RC was associated with increased overall mortality, cancer-specific mortality and disease recurrence (hazard ratios: 1.19 (95% confidence interval [CI]: 1.11-1.27, P < 0.00001), 1.17 (95% CI: 1.06-1.30, P = 0.002), 1.14 (95% CI: 1.03-1.27), respectively). [48] Similarly, Abel et al. reported that intraoperative, and not postoperative transfusion, was linked to worse survival and a higher possibility for recurrence. [49] Whereas, Buchner et al. recorded a negative effect of transfusion in a cohort of 722 patients after 26-month follow-up irrespective its timing [50] and after adjusting for cancer stage. In the same fashion, Siemens et al. reported the negative impact of blood transfusions, by showing that it also increases LOS and re-admission rates. [51] On the other hand, a two-center retrospective study of 1060 patients, did not concur with the above reports. [52] When looking at the four published prospective randomized trials and the recent meta-analysis by Tan et al., we see several variables, which limit us from drawing "conclusive findings." [44] These differences consist of patient and tumor characteristics, the level of surgical experience, the surgical volume, the clinical pathway used, the types of urinary diversion (neobladder or ileal conduits), and the application of the extra-or intracorporeal approach. The small number of patients, the short follow-up and the nonmulticenter character of many of the published articles add further to their limitations. The conclusion is that RARC is better compared to open surgery regarding blood loss and wound complications and worse in operative time. [44] RARC and ORC performed equally in postoperative complications, positive surgical margins (PSM), resected lymph nodes and LOS.
The Memorial Sloan Kettering Cancer Center has published the largest RCT to date. [53] However, in this study, there are also apparent limitations: It is a single-center trial and low-powered (58 ORC-60 RARC). All RARCs were performed extracorporeally, almost 50% of the patients in both arms received a neobladder, and most notably, the study was designed to detect a statistical difference of 20% in Clavien grade 2-5 complications. The authors acknowledged the fact that if the difference was set to 10% or 15%, the outcome might have been different. The same limitations are seen in the other three RCTs. Thus, we have to await the results from the RAZOR study, which will be the largest noninferiority RCT with more than 320 patients, from 15 institutions. [54] SURVIVAL OUTCOME MEASURES Table 3 summarizes the oncological end-points from traditional ORC series from high-volume centers, as well as RARC versus ORC series, including the 4 RCTs and meta-analyses. [41, 44, An overall conclusion that can be drawn from the above studies, further supported by the fact that long-term data are now available, is that RARC is equivalent to ORC in terms of oncological efficacy.
Concerning lymph node dissection, which is a crucial part of the procedure from an oncological viewpoint, it has been shown that RARC can achieve the same or even better lymph node yields than ORC. Li et al. have reviewed nine comparative RARC versus ORC studies with 874 patients, [36] concluding that RARC removed at least two nodes more than ORC (WMD: 2.25; 95% CI, 0.57-3.94; P = 0.009). Four systematic analyses, between 2013 and 2017 were in agreement with the above results. On the other hand, the RCTs and their meta-analysis did not show any difference.
Another critical oncological variable is PSM. The first meta-analysis confirmed that PSM have a statistically significant negative effect on the survival outcomes.
[80] ORC=Open radical cystectomy, RARC=Robot-assisted radical cystectomy, LNY=Lymph node yield
The systematic reviews and the meta-analysis of the RCTs show that RARC and ORC have comparable margin rates. A systematic review for RARC estimated a 5.6% (0%-26%) positive surgical margin rate. [26] However, when adjusted for surgeon experience, the margin rates ranged between 4% and 9%. pT2 and pT3-4 disease are associated with positive margins in 1%-1.5% and 0%-25%, respectively. The IRCC database (n = 939) showed an 8% positive margin rate. [27] Similar margin rates are seen in ORC studies from high-volume centers (4.2%-8.6%) [ Table 3 ]. In the newly announced results of the RAZOR study, overall margin rates were similar for RARC and ORC, but RARC had 
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ORC Hautmann et al. [55] When looking at survival end-points, the results of RARC are promising and appear equivalent to the results of ORC. A systematic review of the oncological outcomes of RARC, using the IRCC dataset [26] reported that 5-year disease-free survival, cancer-specific survival (CSS), and overall survival (OS) rates ranged between 53%-74%, 66%-80%, and 39%-66%, respectively. There was no statistically significant difference bwteen ORC and RARC. The results of the RAZOR study confirmed the oncological equivalence of the two approaches, considering that the noninferiority design had the 2-year progression-free survival as the end-point.
[47] However, significant heterogeneity and overlapping between the included studies creates issues in the interpretation of the results.
The IRCC provided an updated analysis of the oncological outcomes of RARC. [27] In a median follow-up of 44 months, the 5-year recurrence-free survival (RFS), CSS, and OS were 67%, 75%, and 50%, respectively. While acknowledging that 38% of the cohort (n = 702) had advanced disease (pT3-4) and 21% were lymph-node positive, the published survival rates are encouraging.
Snow-Lisy et al. reported outcomes for both RARC and laparoscopic RC patients with the current longest published follow-up of 12 years. [81] The 5-year CSS rate was 70% for this cohort.
In the Karolinska Institute series of 113 consecutive totally intracorporeal RARC, with a median follow-up of 25 months, cancer-specific survival was 81% at 3 years and 67% at 5 years. [82] Tan et al. published one of the few studies comparing ORC to RARC with totally intracorporeal urinary diversion. [83] In this study, a total of 184 patients, equally distributed, with 33.8 months of follow-up, found no difference in the recurrence-free survival and the recurrence sites.
There has been debate as to whether RARC negatively impacts early recurrence patterns due to inadequate resection or pneumoperitoneum; so far, there is no good evidence to support this viewpoint. A comparison of extracorporeal RARC versus ORC concluded that RARC exhibited different recurrence patterns, suggestive of higher rates of extrapelvic and peritoneal carcinomatosis. [84] However, the study was shown to have no statistical evidence to support these views. [85] Recurrence following RC often occurs early, with >80% of recurrences occurring within the first 2 years. [86] The ERUS Scientific Working Group reported on early recurrence patterns among 717 patients who underwent RARC with intracorporeal urinary diversion. RFS at 3, 12, and 24 months was 95.9%, 80.2%, and 74.6%, respectively. Distant recurrences most frequently occurred in the bones, lungs, and liver, and pelvic lymph nodes were the most common site of local recurrence. This multi-center series identified five patients (0.7%) with peritoneal carcinomatosis and two patients (0.3%) with metastasis at the port site (wound site) concluding that "unusual" recurrence patterns were not identified and that recurrence patterns appear similar to those in ORC series. [86] The oncological equivalence of RARC and ORC approaches further highlights the urgent necessity for improved neoadjuvant and adjuvant chemotherapeutic regimens, which aim to augment the efficacy of surgery and improve patient survival outcomes.
FUNCTIONAL OUTCOMES
Continence and potency are the most important quality indicators for the neobladder patients. Unfortunately, there is a lack of data, which makes the comparison for RARC and ORC problematic. Looking at ORCs performance from the 2012 EAU International Consultation on Bladder Cancer, reviewing cases between 1970 and 2012, day-time and night-time 
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Bochner et al. [53] continence was achieved in 85%-90% and 60%-80%, respectively. [4] Tyritzis et al. published the Karolinska Institute series which included functional outcomes from 70 RARCs with neobladder diversion. [87] Nineteen males (90.5%) and two out of three (66.7%) females were continent (0-1 pad/day) at 12 months. Sixteen patients that received a nerve-sparing RARC were potent with or without medication at 12 months. In Table 4 , the published RARC studies of neobladders with functional outcomes are shown. [17, 28, 31, [87] [88] [89] [90] [91] Since many techniques for the creation of neobladders have been described, urodynamic data would be an interesting indicator of functional continence outcomes. Satkunasivam et al. compared RARC with intracorporeal neobladder with ORC, stating that the RARC neobladder had similar urodynamic characteristics, but with inferior daytime continence. [91] Patient urinary bother scores were similar between the two procedures. The limitations of this study include its retrospective nature, its low power in patient numbers (28 RARC, 79 ORC) and a short follow-up for RARC (9.4 months) compared to the 62.1 months for ORC. [91] COST COMPARISON Cost analysis can be a challenging task due to differences between the individual health-systems, public insurance systems, and other parameters. In addition, indirect costs are not taken into account, as these are reflected by readmissions and the high acquisition and maintenance fees of the robot, limits further our ability to make a precise evaluation. Table 5 provides a summary of the available cost studies to date.
Lee et al. estimated that the costs of RARC with ileal conduits, cutaneous continent diversion and neobladders were $20,659, $22,102, and $22,685, respectively, compared to $25,505, $22,697 and $20,719 for ORC. [92] The dominant cost driver in the study was hospital stay, showing that RARC could be less expensive than ORC with a reduced hospital stay. Similarly, Leow et al. concluded that RARC could become cost-efficient if the operation time was <6 h and the hospital stay <1 week. [37] This was the first study that calculated all 90-day direct costs, including supplies. In this study, RARC had less major postoperative complications, which decreased the overall costs. [37] Another study based on the surveillance, epidemiology, and end results program-Medicare linked data concluded that RARC was more expensive when looking at perioperative, 30-and 90-day costs. [41] The statistically significant difference ranged between $3000 and 4000 ($24051 [interquartile range (IQR) $15332-$32078] vs. $21 637 [IQR $12567-$32 460], P = 0.08). Finally, the most recent cost analysis by Bansal and associates suggested that RARC was more expensive than ORC by 18.9%. The key cost drivers were operative time, hospitalization time, and annual surgical volume. [97] None of the current publications on cost have taken into account the time for patients to get back to "normal activities," following discharge from the hospital. The need for home-care is an important cost and the impact of minimally invasive surgery on this aspect of health economics has to date been under-investigated.
An update on health economics for muscle-invasive bladder cancer showed that the economic burden would be decreased if the surgical complications could be reduced and if neoadjuvant chemotherapy could be utilized more since it improves the quality of life and survival of the patients. [98] [95] 2012 224 1444 Worse Better NA NA Mmeje et al. [96] 2013 NA Worse Better Better Worse NA Leow et al. [37] 2015 2101 34,672 Worse Better NA NA Bochner et al. [53] 2015 64 58 Worse Better NA NA Hu et al. [41] 2016 439 7308 Worse Better NA NA
ORC=Open radical cystectomy, RARC=Robot-assisted radical cystectomy, NA=Not available CONCLUSION RC is one of the most challenging and morbid surgical procedures, in which the surgeon has to provide the best outcome in terms of oncological control, complications, and functional outcomes. Experience of the surgeon and the center, has shown to positively impact outcomes. However, the procedure itself might not be enough for cure, since we are dealing with an aggressive cancer. Survival may be improved in the future by optimal neoadjuvant or adjuvant chemotherapy protocols. Apart from extirpating completely the disease, the complications of surgery need to be reduced. The current evidence indicates that RARC achieves better results in terms of blood loss, transfusion rates and hospital stay with an equivalent oncological outcome compared to ORC. On the other hand, the cost of RARC is a significant drawback. Future RCTs are awaited along with the further refinement of surgical technique and peri-operative patient management.
